Real-World Data on Olaparib in Relapsed BRCA-mutated Ovarian Cancer: A Multicenter GINECO RETROLA Cohort Study.

Date publication

février 2023

Journal

Anticancer research

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BENGRINE-LEFEVRE Leila , Dr GAVOILLE Céline

Tous les auteurs :
Bourien H, Lefevre LB, Mouret-Reynier MA, Asselain B, Lucas B, Gavoille C, Cornila C, Gavoille L, Colomba E, Patsouris A, Fabbro M, Chakiba C, Toussaint P, Simon H, Berton D, Garbay D, Tixidre CG, Coeffic D, Morvan A, Collard O, DE LA Motte Rouge T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/36697069

Résumé

Olaparib was approved in 2014 by the European Medicines Agency (EMA) as maintenance treatment for patients with breast cancer gene (BRCA)-mutated platinum-sensitive relapsed high-grade epithelial ovarian cancer (EOC) following the results of the Study 19. We present the results of a national real-world study on the effectiveness of olaparib in relapsed BRCA-mutated EOC patients.

Mots clés

BRCA, BRCA mutation, Ovarian cancer, PARPi, olaparib, platinum, relapsed ovarian cancer, routine clinical practice

Référence

Anticancer Res. 2023 02;43(2):653-662